Bausch & Lombの空売り状況は、投資家がBausch & Lombの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Bausch & Lomb (NYSE:BLCO) 株価情報, 空売り情報

Bausch & Lomb

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Bausch & Lomb Corp

President Donald Trump's <a href="https://www.benzinga.com/news/25/02/43527354/elon-musks-expanding-government-role-far-beyond-appropriate-gop-senator-warns">decision to freeze the U.S. Agency for International Development's $40 billion budget</a> is drawing praise from authoritarian leaders who have long sought to silence independent media in their countries.
&#8220;[Russian President Vladimir] Putin has been trying to kill independent media for God knows how many years now. Ironically the country that has this free speech is now about to give it the death blow,&#8221; Derk Sauer, founder of the online newspaper Moscow Times, <a href="https://www.ft.com/content/10b6a51f-35d4-4f17-86ff-15bc9751f73d">told the Financial Times last week</a>.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
The freeze halts $268 million allocated by Congress for &#8220;independent media and the free flow of information&#8221; globally, according to Reporters Without Borders. The impact spans from Eastern Europe to Latin America, with many independent outlets facing immediate funding crises, the Financial Times reported.&nbsp;
Russian officials celebrated the move. Dmitry Medvedev, deputy chair of the Russian security council, praised the &#8220;smart move to plug USAID&#8217;s deep throat,&#8221; while Hungarian government officials called the freeze &#8220;refreshing,&#8221; according to the Financial Times..
Trending: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a>
The cuts threaten critical investigative journalism networks. The Organized Crime and Corruption Reporting Project, known for investigations like the Panama Papers, told the Financial Times it will lose over a quarter of its budget. &#8220;The short-term impact is really brutal. Like others, we are trying to find alternative sources of funding. Many will find it difficult to survive,&#8221; Paul Radu, OCCRP co-founder, told the newspaper.&nbsp;
In Belarus, at least six independent news outlets in exile reported complete funding cessation. Ukrainian media, heavily dependent on U.S. grants, face similar risks. Russia&#8217;s Meduza, a major independent outlet, called an emergency board meeting to discuss its future, the Financial Times reported.&nbsp;
Trump amplified conspiracy theories about the program on Truth Social, falsely claiming billions were &#8220;stollen&#8221; [sic] by mainstream media as &#8220;payoffs.&#8221; While the U.S. government purchases media subscriptions, it does not directly fund major Western news organizations.
See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it">Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</a>
For exiled journalists, the impact is immediate. In New York, Russian journalists studying on USAID grants expect to lose housing and living stipends next week. &#8220;First, you get expelled by Putin. Then this,&#8221; one journalist told the Financial Times, requesting anonymity due to ongoing funding negotiations.
A U.S. official suggested some funding might resume after the 90-day review, but media observers warn many outlets cannot survive the gap. &#8220;We&#8217;ve been told to stop working, we cannot spend any money, there is no cash coming in,&#8221; one Balkans-based official said to the Financial Times.
Image via Shutterstock Read Next:
<ul>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share! </a></li>
</ul>

News

'Putin Has Been Trying To Kill Independent Media For Years'—Now Trump Is Helping

Social Security is one of the most critical safety nets for retirees in the U.S., but it <a href="https://www.benzinga.com/personal-finance/24/05/38943129/social-security-fears-go-viral-should-you-claim-early-like-dave-ramsey-says">faces a funding shortfall</a> that could result in benefit cuts within the next decade. While some argue for raising the retirement age or reducing payouts, labor economist Teresa Ghilarducci believes the real solution is increasing revenue.
Don't Miss:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>
Ghilarducci, a professor of economics at The New School, suggests that requiring the wealthiest Americans to contribute more to Social Security could significantly reduce the deficit. &#8220;If <a href="https://www.benzinga.com/news/25/01/42821537/15-minutes-into-2025-elon-musk-was-done-with-social-security-tax-meanwhile-94-of-americans-take-the-entire-year">Elon Musk paid for Social Security</a> just on his salary for the entire year and some of his capital gains were taxed to fund Social Security, just one person, it would save 1/20 of the deficit in Social Security,&#8221; she said in a 2024 Bloomberg <a href="https://www.youtube.com/watch?v=ok9gzE5-8wk">interview</a>. &#8220;Imagine broadening that out to maybe 20,000 other people.&#8221;
<h2 class="wp-block-heading">Public Support for Higher Taxes on the Wealthy</h2>
A recent <a href="https://www.nasi.org/wp-content/uploads/2025/01/NASI_SocialSecurityat90.pdf">survey</a> from multiple organizations, including AARP and the U.S. Chamber of Commerce, found that most Americans support tax increases to maintain Social Security benefits. Eighty-five percent of respondents said they would rather see taxes increase than their benefits cut.
Trending: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a>
The most popular proposal? <a href="https://www.benzinga.com/personal-finance/24/11/42217382/bernie-sanders-demands-scrap-the-cap-on-social-security-taxes-its-absurd-a-billionaire-pays-same-amount-as-middle-class-earners">Eliminating the payroll tax cap</a> for earnings above $400,000. Currently, Social Security taxes only apply to income up to $176,100 in 2025, meaning high earners stop contributing after that threshold. Raising or removing the cap would require top earners to pay more and increase their eventual benefits.
Another widely supported measure is gradually increasing the payroll tax rate from 6.2% to 7.2% for both workers and employers. The incremental change would generate more funding without significantly burdening middle-class Americans.
<h2 class="wp-block-heading">The Myth of Working Longer as a Solution</h2>
While some believe people should work longer to improve retirement security, Ghilarducci strongly disagrees. &#8220;Not everyone is living longer,&#8221; she explained. While wealthier Americans in white-collar jobs often have longer life expectancies, many blue-collar and service workers face declining health due to physically demanding work, stress, and economic hardship. &#8220;A lot of jobs that aren&#8217;t blue-collar have become pink-collar … requiring a lot of heavy lifting, stooping and bending. Those jobs break bodies down,&#8221; she said.
See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
<h2 class="wp-block-heading">A New Retirement Plan for Millions</h2>
Ghilarducci also backs a national retirement savings plan that would automatically enroll workers who don&#8217;t have access to employer-sponsored pensions. The Retirement Savings for Americans Act would create a government-administered pension plan with mandatory contributions. Workers earning below the median income would receive a 5% government match, helping them build long-term savings.
She argues that this model, which resembles pension systems in other developed nations, is far superior to the current 401(k) system, which she calls a &#8220;mistake.&#8221; &#8220;<a href="https://www.benzinga.com/content/43571028/inflation-proof-your-retirement-why-401-k-s-may-fall-short-and-what-to-do-instead">The 401(k) system was a mistake</a> if it was meant to be the retirement system for all Americans. It was meant to supplement SS and pensions.&#8221;
Read Next:
<ul>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100</a>.</li>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
</ul>
Image via Shutterstock

Labor Economist Says Musk Paying Full Annual Social Security Taxes Would Cut The Deficit By 1/20 – 'Imagine Expanding That To 20,000 Others'

French President Emmanuel Macron has rejected the proposal by President Donald Trump to convert Gaza into a real estate project. Macron emphasized the need for respect for Palestinians and their Arab neighbors.
What Happened: Macron, in a CNN <a href="https://edition.cnn.com/2025/02/11/europe/macron-trump-gaza-real-estate-intl/index.html">interview</a>, stressed that the Gaza issue requires a political solution rather than a real estate one. He criticized the idea of displacing 2 million Gazans, stating, &#8220;You cannot say to 2 million people, &#8216;okay, now guess what? You will move.'&#8221;
&#8220;The right answer is not a real estate operation, this is a political operation,&#8221; said the French president.
Trump&#8217;s proposal, which has sparked controversy, involves relocating Palestinians from Gaza to Egypt and Jordan, while the U.S. takes long-term ownership of the enclave. He envisions transforming Gaza into a &#8220;Middle Eastern Riviera.&#8221;
Macron has consistently disagreed with Israeli Prime Minister Benjamin Netanyahu over Israel&#8217;s military operations in Gaza and Lebanon. In October 2024, France suspended arms exports to the Israel Defense Forces, urging other nations to follow suit.
Macron&#8217;s comments come amid a wave of international criticism, including from the United Nations and Spain, against Trump&#8217;s plans. The proposal has also sparked plans for redevelopment of Gaza by far-right settler groups in Israel, which would be illegal under international law.
Read Next: <a href="https://www.benzinga.com/news/global/25/02/43643471/trump-administration-secures-release-of-cannabis-prisoner-marc-fogel-from-14-year-russian-sentence">Trump Administration Secures Release Of Cannabis Prisoner Marc Fogel From 14-Year Russian Sentence</a>
Why It Matters: Trump&#8217;s proposal to &#8220;take over the Gaza Strip,&#8221; level it, and rebuild the area after Palestinians are sent elsewhere has been <a href="https://in.benzinga.com/news/25/02/43503385/trumps-gaza-plan-for-seaside-resort-faces-global-pushback">widely rejected</a> by world leaders. They argue that moving nearly 2 million Palestinians from Gaza is tantamount to ethnic cleansing.
Arab foreign ministers have also&nbsp;<a href="https://www.benzinga.com/markets/equities/25/02/43420541/arab-nations-reject-trumps-controversial-gaza-plan-heres-why">rejected</a>&nbsp;Trump's suggestion to transfer&nbsp;Palestinians from Gaza to neighboring&nbsp;Egypt and Jordan, calling it a destabilizing move that would threaten peace in the region.
Despite the global pushback, Trump, in a White House meeting with Jordan's King Abdullah, reiterated his threat that the U.S. will take control of the Gaza Strip and move the Palestinians living there to either Jordan or Egypt or somewhere else, as <a href="https://in.benzinga.com/news/25/02/43637482/trump-gaza-cherish-it-white-house-meeting-with-jordans-king-abdullah">reported</a>.
Photo by Frederic Legrand &#8211; COMEO on Shutterstock
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

General

Emmanuel Macron Rejects Trump's Plan Of Turning Gaza Into A Resort: 'The Right Answer Is Not A Real Estate Operation'

Anthropic, a leading AI company <a href="https://www.benzinga.com/24/11/42141911/amazon-and-anthropic-deepen-4-billion-ai-partnership-with-claude-35-launch">backed by Amazon</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NYSE">AMZN</a>) and <a href="https://www.benzinga.com/government/24/10/41528255/googles-2b-investment-in-anthropic-under-scrutiny-uk-opens-competition-inquiry">Google</a>, is reportedly having a seemingly contradictory stance on artificial intelligence. While the company actively promotes AI use in the workplace and develops AI-driven hiring tools, it has a strict rule for job seekers: do not use AI when applying for their positions.
<h2 class="wp-block-heading">The Double Standard</h2>
As an individual noticed and Futurism reported on, Anthropic's job application form explicitly states:
&#8220;While we encourage people to use AI systems during their role to help them work faster and more effectively, please do not use AI assistants during the application process. We want to understand your personal interest in Anthropic without mediation through an AI system, and we also want to evaluate your non-AI-assisted communication skills.&#8221;
Don't Miss:
<ul>
<li>Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-nancy-pelosi">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>
The company profits from AI-powered hiring processes yet restricts candidates from using the same tools to improve their chances in an increasingly competitive job market. Meanwhile, AI is being widely adopted across hiring processes, with 98.4% of Fortune 500 companies using AI to filter applications and 43% of companies either using or planning to use AI for interviews, according to Jobscan.&nbsp;
<h2 class="wp-block-heading">Anthropic's AI Ambitions</h2>
Anthropic is at the forefront of AI development, <a href="https://www.benzinga.com/news/24/06/39426605/google-amazon-backed-openai-rival-anthropic-unveils-claude-3-5-sonnet-its-most-powerful-ai-yet">competing with OpenAI</a> and other major players. The company recently saw its annualized revenue surge to $1 billion, a tenfold increase from the previous year. It is also reportedly <a href="https://www.benzinga.com/25/01/43127416/anthropic-gains-big-with-google-backing-aiming-for-60-billion-valuation-and-surging-ai-revenue">securing $2 billion in funding</a>, which could triple its valuation to $60 billion.
Backed by Amazon's $8 billion investment and Google's recent $1 billion contribution, Anthropic is pushing forward with AI advancements. CEO Dario Amodei <a href="https://www.benzinga.com/markets/25/01/43094410/jeff-bezos-backed-anthropic-ceo-predicts-ai-will-surpass-human-intelligence-by-2027-but-warns-to-watch-out-for-negative-consequences">has predicted</a> that AI could surpass human intelligence within two to three years. He recently stated that Artificial General Intelligence—AI with human-level capabilities—could emerge by 2026 or 2027, barring setbacks like data shortages, GPU production issues, or scalability problems.
Trending: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a>
While AI companies like Anthropic push for rapid advancements, they also set rules that seem to favor employers over job seekers. The rise of AI-driven hiring has already overwhelmed recruiters, leading to a cycle where companies turn to AI to sort through AI-generated applications.
Anthropic's policy highlights a growing concern. AI is being used to reshape the job market, but workers are being told they can't use it to compete. As both sides of hiring increasingly rely on AI, critics argue that companies must set fair and transparent standards—or risk creating a system where only employers benefit from AI's efficiencies.
For now, if you're applying to Anthropic, leave AI out of it. But once you're hired, feel free to use it all you want.
Read Next:
<ul>
<li>Built on the trusted network of Fortune 500 companies, <a href="https://www.benzinga.com/money/web3-enabler-the-most-boring-blockchain-company-partners-with-salesforce">this blockchain company partners with Salesforce to uproot lengthy and expensive B2B transactions, and you can invest with just $100.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>

AMZN

Amazon And Google-Backed AI Firm Anthropic Urges Job Seekers: Please Don't Use AI To Apply Here

Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) has outperformed the market over the past 20 years by 2.35% on an annualized basis producing an average annual return of 10.76%. Currently, Humana has a market capitalization of $30.99 billion. 
Buying $100 In HUM: If an investor had bought $100 of HUM stock 20 years ago, it would be worth $764.30 today based on a price of $257.34 for HUM at the time of writing.
<h3>Humana's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739317568_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Humana Stock In The Last 20 Years

NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) has outperformed the market over the past 20 years by 28.85% on an annualized basis producing an average annual return of 37.26%. Currently, NVIDIA has a market capitalization of $3.26 trillion. 
Buying $100 In NVDA: If an investor had bought $100 of NVDA stock 20 years ago, it would be worth $62,469.62 today based on a price of $133.02 for NVDA at the time of writing.
<h3>NVIDIA's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739316646_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NVDA

$100 Invested In NVIDIA 20 Years Ago Would Be Worth This Much Today

<a href="https://www.benzinga.com/startups/25/01/43391017/2-trillion-by-2026-elon-musks-ambitious-push-to-reinvent-government-spending-with-silicon-valley-powerhouses">Elon Musk</a> isn't worried about Donald Trump stopping the rise of electric cars. In fact, he thinks it's impossible. "At this point, I think that sustainable transport is inevitable," Musk told investors.&nbsp;
Musk compared the shift to EVs to the transition from horse-drawn carriages to automobiles. "Even if you were the biggest horse advocate on Earth, you couldn't stop the advent of the automobile. And you can't stop the advent of electric cars," he said on a call late last month to discuss Tesla's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) latest quarterly results.&nbsp;&nbsp;
The biggest hurdle for EVs used to be range, but Musk says that's no longer an issue. With more charging infrastructure and better battery technology, people aren't as hesitant to switch. Still, the political scene is shifting, and some wonder what that means for Tesla and the industry as a whole.&nbsp;&nbsp;
Don't Miss:
<ul>
<li>Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-nancy-pelosi">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>
One of Trump's first moves in office was to undo Joe Biden's goal of having 50% of new car sales be electric by 2030. He also wants to get rid of the federal EV tax credit, which gives buyers up to $7,500 in incentives.&nbsp;
That could make EVs a harder sell, but Musk isn't too concerned. In fact, he's actually in favor of ending those subsidies.&nbsp;
"Take away the subsidies. It will only help Tesla," <a href="https://x.com/elonmusk/status/1813112958157005259?lang=en">he said on X </a>last July. His argument? Tesla has already built a strong EV business, while other automakers still rely on incentives to stay competitive.&nbsp;&nbsp;
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
That doesn't mean everything is smooth sailing for Tesla. According to Electrive, EV sales in the U.S. grew by only 7.3% in 2024, reaching 1.3 million units. That's just a slight bump from 7.8% to 8.1% of total car sales. Meanwhile, Tesla's own sales dropped by 5.6% to 633,762 vehicles—their first annual decline in over a decade.&nbsp;&nbsp;
But Musk believes Tesla's real edge isn't just in electric cars; it's in self-driving technology. "There is a path where Tesla is worth more than the next top five car companies combined&#8230; and that is overwhelmingly due to autonomous vehicles and autonomous humanoid robots," he said on the Jan. 30 earnings call.&nbsp;&nbsp;&nbsp;
See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it">Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</a>
Tesla is also making adjustments based on new policy changes. For example, the company had planned to expand into Mexico, but Musk recently put that on hold after <a href="https://www.benzinga.com/startups/25/02/43493701/fed-chair-jerome-powell-faces-trumps-pressure-the-president-cant-fire-me-as-interest-rates-hold-steady-at-4-25-4-5">Trump </a>suggested heavy tariffs on Mexican-made cars. "Trump has said that he will put heavy tariffs on vehicles produced in Mexico, so it doesn't make sense to invest in Mexico," Musk said on a separate earnings call in July amid the 2024 presidential campaign.&nbsp;
Despite these challenges, Tesla isn't slowing down. The company is rolling out a driverless ride-hailing service in Austin within the next six months and is on track to produce autonomous "cybercabs" by 2026. It's also planning to unveil a working prototype of their Optimus humanoid robot in 2025.&nbsp;&nbsp;
Read Next:
<ul>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

Startups

TSLA

Elon Musk: 'You Can't Stop The Advent Of Electric Cars'—Says EV Success Is As Inevitable As Cars Replacing Horses

Jones Trading analyst Jason Weaver maintains Rithm Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RITM#NYSE">RITM</a>) with a Buy and maintains $12.5 price target.

Price Target

Analyst Ratings

RITM

Jones Trading Maintains Buy on Rithm Capital, Maintains $12.5 Price Target

Barrington Research analyst Gary Prestopino maintains Liquidity Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDT#NASDAQ">LQDT</a>) with a Outperform and maintains $40 price target.

LQDT

Barrington Research Maintains Outperform on Liquidity Services, Maintains $40 Price Target

Offerings

Flowers Foods Prices Public Offering Of $500M Of 5.750% Senior Notes Due 2035 And $300M Of 6.200% Senior Notes Due 2055

Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) has outperformed the market over the past 5 years by 5.19% on an annualized basis producing an average annual return of 17.64%. Currently, Baker Hughes has a market capitalization of $46.70 billion. 
Buying $1000 In BKR: If an investor had bought $1000 of BKR stock 5 years ago, it would be worth $2,143.31 today based on a price of $47.19 for BKR at the time of writing.
<h3>Baker Hughes's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739313918_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Baker Hughes Stock In The Last 5 Years

Macquarie analyst Steve Koenig maintains Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) with a Outperform and maintains $200 price target.

DDOG

Macquarie Maintains Outperform on Datadog, Maintains $200 Price Target

HIVE Digital Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.11) by 109.09 percent. This is a 112.5 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $29.23 million which beat the analyst consensus estimate of $26.50 million by 10.30 percent. This is a 6.47 percent decrease over sales of $31.25 million the same period last year.

Earnings

Earnings Beats

HIVE

HIVE Digital Technologies Q3 EPS $0.01 Beats $(0.11) Estimate, Sales $29.23M Beat $26.50M Estimate

Hexcel Prices Offering Of $300M Of Unsecured 5.875% Senior Notes Due 2035

Spire Global Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) shares are sinking in Tuesday&#8217;s after-hours session after it filed a c<a href="https://www.benzinga.com/news/asset-sales/24/11/41944207/spire-global-soars-on-heels-of-241-million-sale-of-maritime-business-plans-debt-payoff">omplaint against Kpler Holding</a>.
What Happened: In a new filing released after the market close on Tuesday, Spire Global announced that it filed a complaint in the Delaware Court of Chancery alleging Kpler failed to close on the <a href="https://www.benzinga.com/news/asset-sales/24/11/41944207/spire-global-soars-on-heels-of-241-million-sale-of-maritime-business-plans-debt-payoff">acquisition of Spire&#8217;s maritime business</a>.
Spire Global entered into a purchase agreement with Kpler in November to sell its maritime business for a cash payment based on an enterprise value of $233.5 million. The company said at the time that it expected the transaction to close in the first quarter. 
Spire Global said it believes all conditions in the purchase agreement have been satisfied or could be satisfied. The company also noted that Kpler agreed to "use best efforts, and to take any and all actions necessary&#8221; to consummate the transaction.
&#8220;The Company believes that Buyer's failure to close is not consistent with the terms of the Purchase Agreement, which do not give Buyer the option to delay closing once all closing conditions have been met,&#8221; Spire Global said in the filing.
See Also: <a href="https://www.benzinga.com/news/earnings/25/02/43641962/lyft-q4-earnings-revenue-beat-gross-bookings-up-15-new-buyback-our-biggest-competition-is-inertia">Lyft Q4 Earnings: Revenue Beat, Gross Bookings Up 15%, New Buyback — &#8216;Our Biggest Competition Is Inertia&#8217;</a>
As a result, Spire Global asked the courts to order Kpler to satisfy the purchase agreement obligations and close the deal.
&#8220;There is no assurance as to what action the Delaware Court of Chancery will take with respect to the proceeding initiated by the Company and there is no assurance as to whether or not the Transactions will be consummated on the terms contemplated or at all,&#8221; the company said.
Price Action: <a href="http://benzinga.com/quote/spir">Spire Global shares</a> were down 43.8% at $11.15 in Tuesday&#8217;s after-hours session at the time of publication, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/25/02/43637482/trump-gaza-cherish-it-white-house-meeting-with-jordans-king-abdullah">Trump Says We Will &#8216;Take Gaza&#8217; And &#8216;Cherish It&#8217; In White House Meeting With Jordan&#8217;s King Abdullah</a></li>
</ul>
This illustration was generated using artificial intelligence via Midjourney.

Movers

SPIR

Spire Global Stock Is Plunging After Hours: What's Going On?

Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) has outperformed the market over the past 20 years by 1.28% on an annualized basis producing an average annual return of 9.69%. Currently, Travelers Companies has a market capitalization of $54.92 billion. 
Buying $1000 In TRV: If an investor had bought $1000 of TRV stock 20 years ago, it would be worth $6,299.71 today based on a price of $242.35 for TRV at the time of writing.
<h3>Travelers Companies's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739313152_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Travelers Companies 20 Years Ago Would Be Worth Today

Lifeway was an early investor in Simple Foods in 2015 and since that time, the Company has already realized a $1.5 million gain in 2019, bringing the total expected net proceeds to Lifeway of approximately $6.5 million.

LWAY

Lifeway Foods Expects To Realize Approximately $5M Of Net Profit Due To Recently Announced Sale Of Simple Foods To Flowers Foods

Marc Fogel, who <a href="https://www.benzinga.com/markets/cannabis/22/06/27780092/russia-sentences-60-something-former-us-diplomat-to-14-years-for-cannabis-possession" target="_blank" rel="noreferrer noopener">was sentenced to 14 years</a> in a Russian penal colony after his 2021 arrest in Moscow for possessing medical marijuana, is coming home.
The White House announced Tuesday, per various news outlets, that it had negotiated Fogel's release.
White House national security adviser Michael Waltz said that Steve Witkoff, President Donald Trump&#8216;s special envoy to the Middle East, was leaving Russian airspace with Fogel, who was declared "wrongfully detained" by President Joe Biden shortly before he left the White House.
Waltz said <a href="https://www.benzinga.com/markets/cannabis/24/08/40111778/russia-prisoner-swap-senators-demand-inclusion-of-cannabis-prisoner-marc-fogel-mom-takes-antony-">Fogel</a>, who previously worked at the&nbsp;U.S. embassy in Moscow and also as an English teacher, would be on U.S. soil by Tuesday night.
&#8220;President Trump, Steve Witkoff and the president&#8217;s advisors negotiated an exchange that serves as a show of good faith from the Russians and a sign we are moving in the right direction to end the brutal and terrible war in Ukraine,&#8221; he said in a statement, <a href="https://www.cbsnews.com/news/marc-fogel-released-russia-trump/">cited</a> by CBS News.
In what CNN <a href="https://www.cnn.com/2025/02/11/politics/marc-fogel-released-russia-trump/index.html">referred</a> to as an extraordinary move, Witkoff personally went to Russia to bring back Fogel, the statement indicated. There has been no known high-level U.S. travel to Russia since the start of the war in Ukraine in February 2022.
"By tonight, Marc Fogel will be on American soil and reunited with his family and loved ones thanks to President Trump's leadership," Waltz's statement said.
Fogel's family <a href="https://www.cnn.com/2025/02/11/politics/marc-fogel-released-russia-trump/index.html">said</a> Tuesday they "are beyond grateful, relieved, and overwhelmed that after more than three years of detention" he is coming home.
"Thanks to the unwavering leadership of President Trump, Marc will soon be back on American soil, free where he belongs," Jane, Ethan and Sam Fogel said in a statement.
Fogel was a legal medical marijuana patient in Pennsylvania where he used cannabis as an alternative to opioids for chronic pain following spinal surgery.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43639754/ukraine-floats-land-swap-with-russia-as-trump-signals-peace-push">Ukraine Floats Land Swap With Russia As Trump Signals Peace Push</a></li>
</ul>
Photo: Melnikov Dmitriy/Shutterstock.com

Cannabis

Government

Global

Trump Administration Secures Release Of Cannabis Prisoner Marc Fogel From 14-Year Russian Sentence

SWTX

SpringWorks Secures FDA Approval Of GOMEKLI For Treatment Of Adult And Pediatric Patients With NF1-PN

Similarweb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NYSE">SMWB</a>) sees FY2025 sales of $285.000 million-$288.000 million vs $285.99 million analyst estimate.

Guidance

SMWB

Similarweb Sees FY2025 Sales $285.000M-$288.000M vs $285.99M Est

Healthcare's resilience makes it a go-to sector during market volatility. With steady demand, innovation, and aging demographics driving growth, investors could consider investing in fundamentally sound stocks like Viatris (VTRS), Bausch + Lomb Corp. (BLCO), and ACADIA Pharmaceuticals (ACAD). With strong industry tailwinds and discounted valuations, these stocks could offer solid upside potential. Continue reading… Despite market volatility, the healthcare sector remains one of the most resilient industries, thanks to its non-cyclical nature and the rising demand for medical services. As the industry evolves, companies that innovate and adapt are well-positioned for growth, offering attractive investment opportunities.
For investors, now might be an opportune time to seek out bargain hunting for healthcare stocks with strong potential, such as Viatris Inc. (<a href="https://stocknews.com/stock/VTRS/">VTRS</a>), Bausch + Lomb Corporation (<a href="https://stocknews.com/stock/BLCO/">BLCO</a>), and ACADIA Pharmaceuticals Inc. (<a href="https://stocknews.com/stock/ACAD/">ACAD</a>).
The healthcare landscape is undergoing a significant transformation with advancements in technology, evolving patient needs, and the growing complexity of medical treatments. Moreover, the aging population is increasing the need for long-term care, medical devices, and essential healthcare services.
At the same time, rising disposable income and changing lifestyles are driving higher healthcare spending, particularly on advanced treatments and pharmaceuticals. Meanwhile, hospitals are adopting bundled payment models and digital tools to enhance efficiency and cut costs.
With the global healthcare services market projected to <a href="https://www.technavio.com/report/healthcare-services-market-industry-analysis">grow by $6.26 trillion</a> at a CAGR of 8.7% between 2023 and 2028, the sector's expansion remains robust.
With that in mind, let's examine the fundamental aspects of the above-mentioned stocks in detail:
Viatris Inc. (<a href="https://stocknews.com/stock/VTRS/">VTRS</a>)
VTRS operates as a healthcare company internationally. The company operates through four segments: Developed Markets; Greater China; JANZ; and Emerging Markets. It provides prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs).
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/e/ebitda.asp">EBITDA</a> margin, VTRS' 30.48% is 440.9% higher than the 5.64% industry average. Similarly, its 27.55% trailing-12-month levered FCF margin is considerably higher than the industry average of 2.57%. Also, its trailing-12-month ROTC of 3.08% compares favorably to the negative industry average of 19.20%.
The stock's forward non-GAAP P/E multiple of 4.18x is 80.1% lower than the industry average of 20.97x. In addition, its forward EV/Sales ratio of 1.84x is 49.6% lower than the industry average of 3.66x.
During the third quarter that ended March 31, 2024, VTRS reported total revenues of $3.75 billion, and its adjusted gross profit was $2.19 billion with a margin of 58%. The company's adjusted EBITDA amounted to $1.28 billion for the quarter. In addition, its adjusted net earnings and EPS stood at $897.60 million and $0.75, respectively.
Analysts expect VTRS' EPS for the fourth quarter (ended December 2024) to come in at $0.57, while its revenue is expected to be $3.60 billion for the same period. However, VTRS' shares have lost 2.3% over the past nine months to close the last trading session at $11.20.
VTRS' bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has an A grade for Value and a B for Growth. Among 149 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical – Pharmaceuticals</a> industry, it is ranked #37. <a href="https://stocknews.com/stock/VTRS/">Click here</a> to access additional ratings of VTRS for Momentum, Stability, Sentiment, and Quality.
Bausch + Lomb Corporation (<a href="https://stocknews.com/stock/BLCO/">BLCO</a>)
BLCO operates as an eye health company with operations across the United States, Europe, Asia, and other international markets. It operates through three segments: Vision Care; Pharmaceuticals; and Surgical, offering a diverse portfolio of around 400 products, ranging from contact lenses and eye care solutions to ophthalmic pharmaceuticals and surgical instruments.
On January 13, 2025, BLCO announced that one of its affiliates had acquired Whitecap Biosciences, LLC, a company developing two novel therapies for glaucoma and geographic atrophy (GA). This acquisition reinforces the company's commitment to expanding its clinical-stage pipeline and advancing innovative treatments in ophthalmology.
BLCO's trailing-12-month EBIT and levered FCF margins of 4.04% and 2.93% are 65.4% and 13.8% higher than their respective industry averages of 2.44% and 2.57%. In addition, its trailing-12-month ROTC of 1.04% compares to the negative industry average of 19.20%.
In terms of forward EV/Sales, BLCO is trading at 2.20x, 39.8% lower than the industry average of 3.66x. Likewise, its forward EV/EBITDA multiple of 11.96x is 9.3% lower than the industry average of 13.19x.
For the third quarter of 2024, which ended on September 30, BLCO's total revenue increased 19% year-over-year to $1.20 billion. Its operating income grew 7.5% from the year-ago value to $43 million. The company's net income amounted to $4 million or $0.01 per share compared to a loss of $84 million or $0.24 per share from the prior-year quarter. Also, its adjusted EBITDA for the quarter came in at $212 million, up 13.4% year-over-year.
Street expects BLCO's revenue for the fourth quarter (ended December 2024) to increase 6.9% year-over-year to $1.25 billion, while its EPS for the same period is expected to come in at $0.23. In addition, BLCO has topped the revenue and EPS estimates in each of the trailing four quarters, which is promising.
Over the past nine months, the stock has gained 20.2%, closing the last trading session at $17.41.
It's no surprise that BLCO has an overall rating of B, equating to a Buy in our POWR Ratings system. It also has an A grade for Value and a B for Growth. Out of 132 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry, it is ranked #34.
Beyond what is stated above, we've also rated BLCO for Momentum, Stability, Sentiment, and Quality. Get all BLCO ratings <a href="https://stocknews.com/stock/BLCO/">here</a>.
ACADIA Pharmaceuticals Inc. (<a href="https://stocknews.com/stock/ACAD/">ACAD</a>)
ACAD is a pharma company that focuses on CNS disorder treatments. Its key product is NUPLAZID for Parkinson's disease psychosis. The company is also developing DAYBUE for Rett Syndrome and has several drugs in various trial phases for conditions like schizophrenia, Prader-Willi syndrome, Alzheimer's disease psychosis, Rett syndrome, and Fragile X syndrome.
On December 11, 2024, ACAD finalized the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million before fees and expenses. As previously disclosed on November 5, 2024, Acadia will allocate one-third of the net proceeds to Neuren Pharmaceuticals Limited under their existing license agreement.
The company intends to use the remaining funds to support its commercial operations, advance R&amp;D initiatives in the central nervous system and rare diseases, and explore future business development opportunities.
 ACAD's trailing-12-month EBITDA margin of 13.40% is 137.8% higher than the industry average of 5.64%. Likewise, its trailing-12-month levered FCF margin of 23.86% compares to the industry average of 2.57%.
In terms of forward EV/Sales, ACAD is trading at 2.61x, 28.6% lower than the industry average of 3.66x. Similarly, its forward Price/Sales multiple of 3.14x is 15.5% lower than the industry average of 3.72x.
During the fiscal third quarter that ended September 30, 2024, ACAD's total revenues increased 18.3% year-over-year to $250.40 million. Its income from operations amounted to $31.64 million, versus a loss of $57.78 million in the prior year's quarter. Moreover, the company's net income and EPS stood at $32.77 million and $0.20, compared to a net loss of $65.18 million and $0.40 per share, respectively.
Analysts expect ACAD's revenue for the fourth quarter (ended December 2024) to increase 20.8% year-over-year to $279.21 million. The company's revenue for the fiscal year 2025 is expected to grow 8.4% year-over-year to $1.06 billion. Moreover, the company topped the consensus revenue estimates in three of the trailing four quarters.
Shares of ACAD have gained 23.3% over the past three months to close the last trading session at $18.40.
ACAD's robust fundamentals are apparent in its POWR Ratings. The stock has an overall rating of B, which equates to Buy in our proprietary rating system.
ACAD has an A grade for Value and Quality. Within the Medical – Pharmaceutical industry, it is ranked #35 out of 149 stocks. <a href="https://stocknews.com/stock/ACAD/">Click here</a> to access additional ACAD ratings for Growth, Momentum, Stability, and Sentiment.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
VTRS shares were trading at $11.32 per share on Wednesday afternoon, up $0.12 (+1.07%). Year-to-date, VTRS has declined -9.08%, versus a 2.91% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/vtrs-blco-acad-3-hidden-bargains-in-the-healthcare-sector/>3 Hidden Bargains in the Healthcare Sector</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Hidden Bargains in the Healthcare Sector

Stifel Nicolaus analyst Thomas Stephan maintained a Hold rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a price tar...

Stifel Nicolaus Remains a Hold on Bausch + Lomb Corporation (BLCO)

Bausch Health Companies (BHC) issued the following update on a potential sale of its subsidiary, Bausch + Lomb Corporation (BLCO), which was disclo...

Bausch Health board determines not to move forward with Bausch + Lomb sale

Bausch & Lomb drops after ending sales process

Jefferies analyst Glen Santangelo downgraded Bausch Health (BHC) to Hold from Buy with a price target of $8, down from $12, after the company annou...

Bausch Health downgraded at Jefferies with B+L deal catalyst removed

Bausch Health cut to hold by Jefferies over B+L update

ACAD

BLCO

VTRS

Press Releases

Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

Comments

Bausch & Lomb

空売り

Bausch & Lomb (NYSE:BLCO) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル